Minimal residual disease assessed by multiparameter flow cytometry in multiple myeloma: impact on outcome in the Medical Research Council Myeloma IX Study.

@article{Rawstron2013MinimalRD,
  title={Minimal residual disease assessed by multiparameter flow cytometry in multiple myeloma: impact on outcome in the Medical Research Council Myeloma IX Study.},
  author={Andy C Rawstron and J. Anthony Child and Ruth M de Tute and Faith Elizabeth Davies and Walter Martin Gregory and Sue E Bell and Alexander J Szubert and Nuria Navarro-Coy and Mark Trehane Drayson and Sylvia Feyler and Fiona M. Ross and Gordon Cook and Graham Hunter Jackson and Gareth J Morgan and Roger G. Owen},
  journal={Journal of clinical oncology : official journal of the American Society of Clinical Oncology},
  year={2013},
  volume={31 20},
  pages={2540-7}
}
PURPOSE To investigate the prognostic value of minimal residual disease (MRD) assessment in patients with multiple myeloma treated in the MRC (Medical Research Council) Myeloma IX trial. PATIENTS AND METHODS Multiparameter flow cytometry (MFC) was used to assess MRD after induction therapy (n = 378) and at day 100 after autologous stem-cell transplantation (ASCT; n = 397) in intensive-pathway patients and at the end of induction therapy in non-intensive-pathway patients (n = 245). RESULTS… CONTINUE READING
Recent Discussions
This paper has been referenced on Twitter 21 times over the past 90 days. VIEW TWEETS

From This Paper

Topics from this paper.

Citations

Publications citing this paper.
Showing 1-10 of 98 extracted citations

Similar Papers

Loading similar papers…